SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **September 21, 2006**

CHEMBIO DIAGNOSTIC, INC.
(Exact name of registrant as specified in its charter)

Nevada	**0-30379**	**88-0425691**
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive offices)
631-924-1135
(Registrant's Telephone Number)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosures.

On September 21, 2006 the Registrant issued the press release titled "Chembio Supports CDC's Timely Recommendation For Routine HIV Testing as the US Conference on AIDS Begins" included herein as Exhibit 99.1.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled "Chembio Supports CDC's Timely Recommendation For Routine HIV Testing as the US Conference on AIDS Begins" issued September 21, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 22, 2006 Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer

Chembio Supports CDC's Timely Recommendation For Routine HIV Testing as the US Conference on AIDS Begins

Chembio to Participate in Conference and Showcase SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM)

N.Y. - September 21, 2006 - Chembio Diagnostics, Inc. (OTCBB:CEMI) strongly supports the U.S. Centers for Disease Control and Prevention's (CDC) HIV testing final recommendations issued this morning that all Americans between the ages of 13 to 64 be tested for HIV as a part of routine medical care. Today's news comes just as the US Conference on AIDS begins in Hollywood, Florida. At the conference, which runs from September 21-25, Chembio will exhibit its two FDA-approved rapid HIV tests, SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM), at booth #803.

Lawrence Siebert, President and CEO of Chembio, commented, "We are pleased the CDC now officially recommends routine HIV testing. Routine testing is essential in the battle against HIV infection and AIDS, in America and globally. We believe our SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) tests will play an important role in helping to identify and control the disease."

Chembio anticipates signing a US marketing agreement while its CLIA (Clinical Laboratory Improvement Act) waiver applications are being reviewed. A CLIA waiver, if granted, would greatly expand the available market for SURE CHECK and STAT PAK from hospitals and certified laboratories to also include public health clinics, doctors' offices and other settings. The Company believes that the guidelines for routine HIV testing that were released by the CDC will be implemented in these settings in the near future.

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP(TM)), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:
The Investor Relations Group 212-825-3210
Investors: James Carbonara
Media: Susan Morgenbesser